Iovance AMTAGVI Sales Surge 52% on In-House Manufacturing

Iovance Biotherapeutics reported accelerating sales momentum for its flagship cancer treatment AMTAGVI at the Wells Fargo healthcare conference, driven by rising demand and transition to internal manufacturing.

AMTAGVI second-quarter sales reached $91 million, representing a 51.7% sequential increase from the $60 million recorded in the first quarter, according to a transcript from Investing.com.

Gross Margins and Manufacturing Expansion

The revenue growth was accompanied by margin improvements as the biotech firm shifted its production processes internally. Gross margins expanded from 41% to 56% as Iovance brought manufacturing entirely in-house, according to the conference presentation.

Bringing production facilities under internal control allows biotechnology companies to reduce third-party contractor fees and optimize supply chain logistics. For cell therapies like AMTAGVI (which rely on individualized patient tissue processing) in-house manufacturing can reduce turnaround times and improve batch consistency.

Market Response and Insider Activity

In the public markets, Iovance Biotherapeutics Inc (IOVA) traded at $8.60, up 5.65% from its previous close of $8.14, according to Finnhub market data.

Simultaneously, regulatory filings show executive activity surrounding the company's equity. A Form 4 was filed on September 10, 2026, reporting insider transactions, according to SEC EDGAR records.

Commercial Scaling for Cell Therapy

These financial and operational metrics illustrate the ongoing commercial scaling of tumor-infiltrating lymphocyte therapies. As Iovance expands authorized treatment centers and increases manufacturing capacity, investors and analysts monitor whether sequential revenue acceleration can offset the high capital expenditures traditionally associated with personalized oncology treatments.